Granzyme B for predicting the durable clinical benefit of anti-PD-1/PD-L1 immunotherapy in patients with non-small cell lung cancer

BACKGROUND: To identify immunotherapy biomarkers, we examined granzyme B levels in peripheral blood PD-1(+) CD8(+) T cells and their relationship with treatment outcomes in patients with non-small cell lung cancer (NSCLC). METHODS: To evaluate the association of granzyme B with response to immunothe...

Descripción completa

Detalles Bibliográficos
Autores principales: Chung, Jae Heun, Ha, Jong Seong, Choi, Jaewoo, Kwon, Sang Mo, Yun, Mi Sook, Kim, Taehwa, Jeon, Doosoo, Yoon, Seong Hoon, Kim, Yun Seong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2022
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904957/
https://www.ncbi.nlm.nih.gov/pubmed/35281415
http://dx.doi.org/10.21037/tcr-21-2506

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8904957/
https://www.ncbi.nlm.nih.gov/pubmed/35281415
http://dx.doi.org/10.21037/tcr-21-2506

Ejemplares similares